Skip to main content
Clinical Trials/ISRCTN14549448
ISRCTN14549448
Completed
未知

ESSENTIEL Hospital: observation of exclusive heart rate reduction effects with ivabradine in angina patients in a hospital setting

Servier Maroc0 sites125 target enrollmentFebruary 7, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
Coronary artery disease (CAD) and angina
Sponsor
Servier Maroc
Enrollment
125
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 7, 2023
End Date
April 2, 2019
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Servier Maroc

Eligibility Criteria

Inclusion Criteria

  • as per current SmPC
  • 1\. Patients 18 years and older
  • 2\. Female or male
  • 3\. Patients with documented stable coronary artery disease with or without left ventricular dysfunction (LVD); example: with angina, history of revascularization, history of myocardial infarction, or angiographic evidence of at least 70% stenosis of one of the major coronary arteries
  • 4\. Patient with stable angina diagnosed more than 6 months ago
  • 5\. HR resting \>70 bpm
  • 6\. Patients inadequately controlled despite an optimal dose of beta\-blockers

Exclusion Criteria

  • according to current SmPC
  • 1\. Known hypersensitivity to the active substance or any of the excipients
  • 2\. Resting heart rate of fewer than 70 beats per minute prior to treatment
  • 3\. Cardiogenic shock
  • 4\. Acute myocardial infarction
  • 5\. Severe hypotension (\<90/50 mmHg)
  • 6\. Severe liver failure
  • 7\. Sick sinus syndrome
  • 8\. Atrial sinus block
  • 9\. Unstable or acute heart failure

Outcomes

Primary Outcomes

Not specified

Similar Trials